Wells Fargo analyst Mohit Bansal downgraded Chinook Therapeutics (KDNY) to Equal Weight from Overweight with a price target of $40, up from $30. The analyst cites the company’s agreement to be acquired by Novartis (NVS) for $40 per share for the downgrade.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KDNY:
- Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
- Chinook announces first patient enrolled in Phase 3 BEYOND study of BION-1301
- Chinook Therapeutics presents data from CHK-336 Phase 1 trial
- Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress
- Chinook Therapeutics downgraded to In Line from Outperform at Evercore ISI